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OBJECTIVE — We prospectively examined the relationship between lung function and risk
of type-2 diabetes and fatal and nonfatal coronary heart disease (CHD) events and investigated
the hypothesis that inﬂammation may underlie these associations.
RESEARCH DESIGN AND METHODS — A prospective study of 4,434 men aged
40–59 years with no history of cardiovascular disease (CHD or stroke) or diabetes drawn from
general practices in 24 British towns and followed up for 20 years.
RESULTS — There were 680 major CHD events (276 fatal, 404 nonfatal) and 256 incident
type2diabetesduringthe20yearsfollow-up.Forcedvitalcapacity(FVC)andforcedexpiratory
volume in 1 s (FEV1) but not FEV1-to-FVC ratio were signiﬁcantly and inversely associated with
incident type 2 diabetes and fatal CHD events (not nonfatal events) after adjustment for age,
potential confounders, and metabolic risk factors. The adjusted relative risk (RR) for type 2
diabetes (Quartile 1 vs. Quartile 4) were 1.59 (1.07–2.56) and 1.74 (1.16–2.61) for FVC and
FEV1, respectively (P  0.03 and P  0.04 for trend). The corresponding RR for fatal CHD were
1.48 (1.00–2.21) and 1.81 (1.19–2.76) (P  0.002 and P  0.0003 for trend). Lung function
was signiﬁcantly and inversely associated with C-reactive protein and interleukin-6; the inverse
associations with type 2 diabetes for FVC and FEV1 were attenuated after further adjustment for
thesefactors(P0.14andP0.11fortrend)butremainedsigniﬁcantforfatalCHD(P0.03
and P  0.01, respectively).
CONCLUSIONS — Restrictive rather than obstructive impairment of lung function is asso-
ciatedwithincidenttype2diabetes(andfatalCHD)withbothassociationspartiallyexplainedby
traditional and metabolic risk factors and inﬂammation.
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T
he association between impaired
lung function and cardiovascular
disease (CVD) morbidity and mor-
tality is well established (1,2) although
themechanismsremainunclear.Reduced
lungfunctionisalsooneofthemanyclin-
ical features associated with type 2 diabe-
tes (3,4). Diabetes has been shown to be
associated with impaired pulmonary
function in a restrictive pattern (3), and
prospective studies have suggested that
reduced lung function may be associated
with the development of type 2 diabetes
(5–8). It has been suggested that inﬂam-
mation may be a possible mechanism un-
derlying the association between lung
function and incident type 2 diabetes and
CVD (6,7,9). Moreover, it has been sug-
gested that lung function is more strongly
associated with risk of fatal rather than
nonfatal coronary heart disease (CHD)
events and has been implicated in in-
creased fatality following a cardiac event
(10). This is of interest given that recent
studieshavesuggestedthatmarkersofin-
ﬂammation, which are associated with
lung function (11), may be more strongly
associated with risk for fatal than risk for
nonfatal vascular events (12,13). While
inﬂammatory markers have been shown
to contribute to—but not fully explain—
the increased CVD risk associated with
reduced lung function (9), the contribut-
ing role of inﬂammation to the associa-
tions between lung function and diabetes
and fatal and nonfatal CHD events sepa-
rately has yet to be explored. We have
examined the prospective relationship
between measures of lung function (in-
cluding forced vital capacity [FVC],
forced expiratory volume in 1 s [FEV1],
andFEV1-to-FVCratio)andincidenttype
2 diabetes as well as with major CHD,
fatal CHD, and nonfatal myocardial in-
farction (MI) separately in middle-aged
men and assessed the contributing role of
inﬂammation (C-reactive protein [CRP]
and interleukin-6 [IL-6]) to these associ-
ations over and above a comprehensive
panel of traditional and metabolic risk
factors. The ﬁndings may also provide
furtherinsightintounderstandingtheun-
derlying associations between type 2 dia-
betes and CHD.
RESEARCH DESIGN AND
METHODS— The British Regional
HeartStudyisalargeprospectivestudyof
CVD comprising 7,735 men aged 40–59
yearsanddrawnfromgeneralpracticesin
each of 24 towns in England, Wales, and
Scotland in 1978–1980. The criteria for
selecting the town, the general practice,
andthesubjects,aswellasthemethodsof
data collection have been reported (14).
Research nurses administered a standard
questionnaire that included questions on
lifestyle and medical history. Physical
measurements including height and
weightweremade,andvenousnonfasting
blood samples were obtained to prepare
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cal and hematological variables. CRP and
IL-6 measurements were only available
for men in the 7th to 24th towns visited
(n4,877).Detailsoflifestylefactorclas-
siﬁcations, social class, and blood pres-
sure and blood lipid measurements have
been reported (14–16). The men were
askedtorecalladoctordiagnosisofCHD,
stroke, diabetes, and a number of other
disorders. Men with recall of a doctor’s
diagnosis of CHD or stroke, known dia-
betics at screening, and with asymptom-
atic hyperglycemia 11.1 mmol/l were
excluded (n  371). We also excluded
men with missing spirometry function
(n  72). After these exclusions, data
were available for a group of 4,434 men,
who became the subjects of this study.
CRP
In 1,531 men who were included in an
earlier case control analysis, CRP was
measured using a sensitive enzyme im-
munoassay (17). In the remainder, CRP
was assayed in Glasgow by ultrasensitive
nephelometry (Dade Behring, Milton
Keynes, U.K.); intraassay and interassay
coefﬁcients of variation were 4.7 and
8.3%, respectively. Using the results of a
calibration study in 295 subjects whose
samples were assayed using both meth-
ods, the results of the earlier CRP assays
were adjusted to the Glasgow assay, for
whichthecurrentCRPinternationalstan-
dard was used by subtracting 0.128
from the earlier log CRP assay (87.9% of
the original value). In a sensitivity analy-
sis,werestrictedtheanalysestothe3,342
men with CRP assayed by the ultrasensi-
tive nephelometric method. The main
ﬁndings remained unchanged.
IL-6
IL-6 was assayed using a high-sensitivity
ELISA (R & D Systems, Oxford, U.K.).
Intraassay and interassay coefﬁcients of
variationwere7.5and8.7%,respectively.
IL-6 data were missing in 183 men.
Lung function
FEV1 and FVC were measured using a Vi-
talograph spirometer (model J49-B2)
with the subject seated. Two consecutive
readings were made 15 s apart and, as per
convention, the maximum of these two
readings was used. FVC is the maximum
volume of air expired during forced expi-
ration and is primarily an indicator of
lung volume. FEV1 is the volume of air
expired in the ﬁrst second of forced expi-
ration and is inﬂuenced by lung volume
and airﬂow obstruction. Cole (18) has
shown that dividing by the height
2 is the
most appropriate way of standardizing
lung function for stature, and this yielded
thebestﬁttothedata(19).FEV1andFVC
were height standardized to the average
height (1.73 m) in the study; thus, height
standardization was FEV1 (FVC)  FEV1
(FVC) multiplied by (1.73/height)
2. The
FEV1-to-FVCratio,anindicatorofairﬂow
obstruction, was deﬁned as the ratio of
raw FEV1 to FVC. While not presented in
the main text, we also considered alterna-
tive analyses using percentage predicted
FEV1 (raw FEV1 divided by predicted
FEV1) and percentage predicted FVC
(rawFVCdividedbypredictedFVC).Pre-
dicted FEV1 and FVC were calculated us-
ingequationsfromareferencepopulation
of nonsmokers that included age and
height as suggested by the European Re-
spiratory Society guidelines (20).
Preexisting undiagnosed CHD and
presence of arrhythmia
The World Health Organization (WHO)
Rosechestpainquestionnairewasadmin-
istered to all men at the initial examina-
tion, and a standard resting 3-lead
electrocardiogram (ECG) was recorded at
rest(15).Anormalrhythmwasdeﬁnedas
sinus rhythm, coronary sinus rhythm, or
sinus arrhythmia. All other statements of
rhythm were treated as an arrhythmia
e.g., sinus rhythm with ventricular extra-
systoles (15). Preexisting undiagnosed
evidence of CHD included evidence of
ischemic heart disease on the WHO
(Rose) chest pain questionnaire or elec-
trocardiographic evidence of myocardial
ischemia or infarction in the absence of a
doctor’s diagnosis of CHD (15).
Follow-up
All the men have been followed up for
all-cause mortality, cardiovascular mor-
bidity, and development of type 2 diabe-
tes from the initial screening in January
1978–July 1980 to June 2008, and fol-
low-up has been achieved for 99% of the
cohort(15,16).Thisanalysisisbasedona
20-year follow-up from initial screening
for each man. Information on deaths was
collected through the established “tag-
ging” procedures provided by the Na-
tional Health Service registers. Fatal CHD
events were deﬁned as death with CHD
(ICD-9 codes 410–414) as the underly-
ing code. A nonfatal MI was diagnosed
according to WHO criteria. Patients who
survived a ﬁrst MI for more than 28 days
andwhodiedthereafterduringfollow-up
wereincludedinthenonfatalgroup.Case
fatality is deﬁned as the proportion of
those major CHD events in which death
occurred during the 28 days after the ﬁrst
event and in which the death certiﬁcate
recorded CHD (ICD-9 codes 410–414).
Evidenceregardingdiabeteswasobtained
by reports from general practitioners and
by biennial reviews of the patients’ notes
(including hospital and clinic correspon-
dence) through to the end of the study
period. Cases are based on self-reported
diagnoses conﬁrmed by primary care
records, an approach which has been val-
idated in the present study.
Statistical methods
The men were divided by quartiles of
FVC,FEV1,andFEV1-to-FVCratio.Cox’s
proportional hazards model was used to
assess the multivariate-adjusted relative
risk (RR) for each quartile compared with
the reference group (lowest quartile). In
the adjustment, age, BMI, systolic blood
pressure (sBP), HDL cholesterol, triglyc-
erides, total cholesterol, blood glucose,
CRP, and -glutamyl transferase (GGT)
(whichhasbeenshowntobeastrongpre-
dictor of type 2 diabetes) (16) were ﬁtted
as continuous variables; all other con-
founders were ﬁtted as categorical vari-
ables. Smoking was ﬁtted as ﬁve groups
(never, former smokers, 1–19 cigarettes
per day, 20–39 cigarettes per day, and
40 cigarettes per day). Differences for
associations between lung function mea-
sures and MI/CHD deaths and nonfatal
eventswereevaluatedusinglikelihoodra-
tio tests based on methods of competing
risk survival analysis (21). The likelihood
ratio tests evaluated the hypothesis that
the associations of lung function were the
sameforMI/CHDdeathsandnonfatalMI.
RESULTS— In the 4,434 men with no
prevalent diabetes or CHD, there were 256
incident cases of type 2 diabetes and 680
major CHD events (276 fatal, 404 nonfatal)
during the 20-year follow-up period.
Table1showsbaselinecharacteristics
andlevelsofbiologicalmarkersaccording
to quartiles of FVC and the FEV1-to-FVC
ratio. FVC was strongly and signiﬁcantly
associated (inversely) with age, current
smoking, physical inactivity, manual so-
cial class, preexisting evidence of undiag-
nosed CHD (but not arrthymias), BMI,
sBP, and metabolic risk factors (triglycer-
ides, blood glucose), markers of inﬂam-
mation (CRP, IL-6, white cell count), and
GGT. Similar associations were seen for
FEV1 with the exception of BMI and
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ciation with FEV1. By contrast, the FEV1-
to-FVC ratio was positively associated
with BMI and blood glucose; no associa-
tion was seen with GGT.
All measures of lung function (FEV1,
FVC, and FEV1-to-FVC ratio) were
strongly (inversely) associated with in-
ﬂammation markers even after adjust-
ment for age, BMI, evidence of CHD,
smoking,physicalactivity,socialclass,al-
coholintake,bloodglucose,triglycerides,
sBP, and HDL cholesterol. This was seen
inbothsmokersandnonsmokers(allP
0.0001). The adjusted standardized re-
gression coefﬁcients for CRP for FEV1,
FVC,andFEV1-to-FVCratiowere0.21,
0.27, and 0.14 for smokers and
0.17, 0.14, and 0.04 for nonsmok-
ers, respectively. For IL-6, the corre-
sponding standardized regression
coefﬁcients were 0.11, 0.12, and
0.06 in smokers and 0.08, 0.10,
and 0.06 in nonsmokers, respectively.
FVC and FEV1 were signiﬁcantly and
inversely associated with risk of type 2
diabetes after adjustment for lifestyle
characteristics, BMI, sBP, metabolic risk
factors(bloodglucose,triglycerides,HDL
cholesterol), and GGT (Table 2). The in-
verse associations seen with FEV1 and
FVC were attenuated after further adjust-
mentforCRPandIL-6(P0.14andP
0.11 for trend, respectively) although the
increased risks in those with low FEV1
remained signiﬁcantly increased when
compared with high FEV1 (Table 2). No
association was seen between the FEV1-
to-FVCratioandincidenttype2diabetes.
When examined separately by BMI
status (28 kg/m
2 and 28 kg/m
2), the
increased risk of type 2 diabetes associ-
ated with low FVC or low FEV1 was more
apparent in the 28 kg/m
2 BMI group.
The adjusted RRs for FVC (Quartile 1 vs.
Table 1—Characteristics at baseline according to quartiles of FVC and FEV1-to-FVC ratio
Quartile
P value 1234
FVC (l) <3.97 3.97– 4.43– 4.87–
Age (years) 53.1 51.4 49.4 47.6 0.0001
Current smokers (%) 49.6 42.5 36.3 38.2 0.0001
Inactive (%) 43.8 38.7 34.8 31.4 0.0001
Heavy drinkers (%) 11.4 10.7 10.6 11.5 0.88
Manual (%) 67.6 62.1 58.3 57.1 0.0001
Evidence of CHD (undiagnosed) (%) 25.9 22.1 19.4 17.0 0.0001
Silent MI (ECG) (%) 2.5 3.0 1.3 0.7 0.0002
Arrhythmia (%) 5.9 6.2 6.0 5.4 0.87
BMI (mg/k
2) 25.6 25.5 25.5 25.0 0.0001
HDL cholesterol (mmol/l) 1.14 1.15 1.15 1.17 0.11
Triglycerides (mmol/l) 1.76 1.72 1.71 1.57 0.0001
Cholesterol (mmol/l) 6.24 6.28 6.30 6.16 0.12
sBP (mmHg) 148.1 145.6 145.4 143.1 0.0001
Glucose (mmol/l) 5.53 5.47 5.47 5.42 0.0001
CRP (mg/l) 1.97 1.31 1.11 0.91 0.0001
IL-6 (pg/ml) 2.89 2.39 2.14 2.01 0.0001
WCC (10
9/l) 7.17 6.95 6.89 6.82 0.0001
GGT (IU/l) 16.4 15.2 14.7 13.7 0.0001
FEV1-to-FVC ratio <0.71 0.71– 0.77– 0.82–
Age (years) 52.2 50.8 49.7 48.7 0.0001
Current smokers (%) 57.9 46.8 37.0 25.2 0.0001
Inactive (%) 41.1 42.3 33.1 32.2 0.0001
Heavy drinkers (%) 15.2 12.3 9.4 9.1 0.0001
Manual (%) 71.2 64.0 56.8 53.0 0.0001
Evidence of CHD (undiagnosed) (%) 25.0 20.2 18.8 20.5 0.001
Silent MI (ECG) (%) 2.3 1.5 2.0 1.8 0.57
Arrhythmia (%) 6.3 5.5 5.8 5.7 0.87
BMI (kg/m
2) 24.7 25.4 25.5 26.0 0.0001
HDL cholesterol (mmol/l) 1.17 1.15 1.14 1.14 0.0001
Triglycerides (mmol/l) 1.60 1.75 1.69 1.72 0.0001
Cholesterol (mmol/l) 6.09 6.32 6.27 6.31 0.0001
sBP (mmHg) 146.8 146.3 144.7 144.4 0.0001
Glucose (mmol/l) 5.42 5.42 5.48 5.53 0.001
CRP (mg/l) 1.68 1.28 1.19 1.03 0.0001
IL-6 (pg/ml) 2.80 2.32 2.23 2.08 0.0001
WCC (10
9/l) 7.32 7.03 6.89 6.62 0.0001
GGT (IU/l) 15.0 15.2 14.6 14.9 0.77
Data are means unless otherwise stated. The numbers in bold indicate the range of FVC and FEV1-to-FVC ratio for the four quartiles. WCC, white cell count.
Lung function, diabetes, and CHD
1992 DIABETES CARE, VOLUME 33, NUMBER 9, SEPTEMBER 2010 care.diabetesjournals.orgQuartile 4) were 1.73 (95% CI 1.03–
2.93) and 1.14 (0.58–2.22) for the two
BMI groups, respectively. The corre-
sponding RRs for FEV1 were 2.05 (1.17–
3.61) and 1.11 (0.56–2.20). However, a
formal test for interaction between FEV1
or FVC and BMI with incident type 2 di-
abetes was not signiﬁcant. Although the
numbers were small, the increased risk
associatedwithlowFEV1—andtoalesser
extent FVC—was also seen in “never
smokers” (Quartile 1 vs. Quartile 4: ad-
justed RR 1.21 [0.53–2.75] and 1.54
[0.63–3.80] for FVC and FEV1, respec-
tively). No interaction was seen with
smoking status.
FVC and FEV1 were signiﬁcantly as-
sociated with major CHD events largely
due to the association with fatal CHD
events (Table 3). No association was seen
for nonfatal events after adjustment for
established risk factors. Comparisons of
differing association between fatal and
nonfatal events showed signiﬁcant/
marginally signiﬁcant differences in the
relationships between FEV1 and FVC and
fatal CHD and nonfatal MI (P  0.04 and
P  0.08, respectively). The inverse asso-
ciation between FVC and FEV1 with fatal
CHD events was attenuated but remained
signiﬁcant after adjustment for CRP and
IL-6 (P  0.03 and P  0.01 for trend)
although the increased risk associated
with low FVC was no longer signiﬁcant
compared with those with high FVC (Ta-
ble 3). Exclusion of the men who devel-
opedtype2diabetesduringthefollow-up
period or men with silent MI on ECG (85
men) made little difference to the ﬁnd-
ings. Although the numbers were small,
the inverse association between FVC and
FEV1 and fatal CHD events after adjust-
ment for CRP and IL-6 was seen in “never
smokers” (Quartile 1 vs. Quartile 4; ad-
justed RR 2.86 [95% CI 0.77–10.66] and
2.41 [0.85–6.85] for FVC and FEV1,r e -
spectively). Case fatality decreased with
increasing lung function after adjustment
for age, and the trend became of marginal
signiﬁcance after adjustment for CRP and
preexisting disease. The FEV1-to-FVC ra-
tio was signiﬁcantly, but weakly, in-
versely associated with fatal CHD events
after adjustment for age (P  0.02 for
trend), but this was attenuated after ad-
justment for established CV risk factors
(adjusted RR for the four quartiles 1.10
[0.76–1.60], 1.13 [0.79–1.63], 0.96
[0.66–1.40] and 1.00).
The percent predicted FVC (FEV1)
was highly correlated with height stan-
dardized FVC (FEV1)( r  0.97), and
models using continuous terms for per-
centpredictedFVCandpercentpredicted
FEV1wereconsistentwiththeaboveﬁnd-
ings using FVC/height
2 and FEV1/height
2
(data not shown).
CONCLUSIONS — In this study of
British middle-aged men without diagno-
sis of CHD or type 2 diabetes, lung func-
tion as measured by FVC and FEV1 was
signiﬁcantlyandinverselyassociatedwith
risk of incident type 2 diabetes and fatal
CHD after adjustment for a wide range of
variables including smoking, physical ac-
tivity, alcohol intake, social class, BMI,
preexisting CHD (undiagnosed), blood
pressure, total cholesterol, metabolic
markers (blood glucose, triglycerides,
HDL cholesterol), and hepatic function.
Interestingly,inﬂammatorypathway(i.e.,
CRP, IL-6) adjustments further attenu-
ated associations between FEV1 and FVC
and type 2 diabetes and fatal CHD. Ob-
structive airways disease per se (as much
as it may be reﬂected by the ﬁrst quartile
of the FEV1-to-FVC ratio [0.71]) was
related neither to type 2 diabetes nor in-
dependently with CHD events. Our ﬁnd-
ings conﬁrm previous studies that have
reported inverse associations between
lung function and type 2 diabetes and
Table 2—Lung function and risk of incident type 2 diabetes during 20 years of follow-up
FVC (l)
P-value trend 1( 3.97) 2 (3.97–) 3 (4.43–) 4 (4.87–)
n 1,095 1,106 1,116 1,117
Rate/1,000 P-years 4.7 3.2 3.2 2.1
Model 1 2.54 (1.74–3.70) 1.58 (1.07–2.34) 1.56 (1.06–2.31) 1.00 0.0001
Model 2 1.94 (1.32–2.86) 1.32 (0.89–1.97) 1.34 (0.90–1.97) 1.00 0.001
Model 3 1.59 (1.07–2.56) 1.14 (0.76–1.71) 1.27 (0.85–1.88) 1.00 0.03
Model 4 1.46 (0.97–2.20) 1.21 (0.81–1.81) 1.03 (0.68–1.55) 1.00 0.14
FEV1 (l)
P-value trend 1( 2.95) 2 (2.95–) 3 (3.41–) 4 (3.81–)
n 1,108 1,107 1,111 1,108
Rate/1,000 P-years 3.9 3.4 3.5 2.2
Model 1 2.05 (1.40–3.01) 1.51 (1.03–2.23) 1.56 (1.07–2.26) 1.00 0.005
Model 2 1.92 (1.29–2.86) 1.35 (0.91–1.99) 1.52 (1.04–2.21) 1.00 0.02
Model 3 1.74 (1.16–2.61) 1.36 (0.92–2.03) 1.35 (0.92–1.98) 1.00 0.04
Model 4 1.67 (1.09–2.56) 1.31 (0.87–1.97) 1.40 (0.94–2.08) 1.00 0.11
FEV1-to-FVC ratio
P-value trend 1( 0.71) 2 (0.71–) 3 (0.77–) 4 (0.82–)
Rate/1,000 P-years 2.5 3.7 3.2 3.6
Age-adjusted 0.67 (0.46–0.96) 0.87 (0.63–1.21) 0.77 (0.55–1.07) 1.00 0.12
Model 1, age-adjusted; Model 2, Model 1  adjusted for age, BMI, smoking, physical activity, alcohol intake, social class, evidence of CHD (undiagnosed); Model
3, Model 2  triglycerides, sBP, HDL cholesterol, blood glucose, and GGT; and Model 4, Model 3  CRP  IL-6. P-years, person-years.
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these ﬁndings further by examining the
role of inﬂammation in explaining these
associations and differentiating between
fatal and nonfatal CHD events.
Lung function and type 2 diabetes
Our results are consistent with other pro-
spective studies that have shown restric-
tive lung function (reduced FVC and
FEV1) but not obstructive pulmonary
function (FEV1-to-FVC ratio) is associ-
ated with the development of type 2 dia-
betes (5–8). Numerous cross-sectional
studies have also suggested a restrictive
pattern of deterioration in lung function
in diabetics (3). Several explanations for
the link between lung function and inci-
dent type 2 diabetes have been proposed
includingmetabolicpathways,inﬂamma-
tory processes, and early life inﬂuences
(6,7). FVC in particular and FEV1 were
associated with metabolic abnormalities
and components of the insulin resistance
syndrome, which is consistent with sev-
eral previous studies that have reported
associations between restrictive lung pat-
terns with glucose metabolism and the
metabolic syndrome (23). We did not
have measures of fasting insulin but si-
multaneousadjustmentformetabolicrisk
markers closely associated with insulin
resistance (BMI, glucose, triglycerides,
and HDL cholesterol) and GGT (a corre-
late of hepatic fat and insulin resistance)
(16) did not fully explain the association.
We observed a strong association be-
tween both restrictive and obstructive
lung patterns and inﬂammatory markers
Table 3—Lung function and risk of all major CHD events, fatal and nonfatal MI events, and case fatality during 20 years of follow-up
FVC (l)
P for trend 1( 3.97) 2 (3.97–) 3 (4.43–) 4 (4.87–)
n 1,095 1,106 1,116 1,117
Major CHD
Rate/1,000 P-years 11.9 (225) 9.9 (189) 7.9 (157) 6.1 (123)
Model 1 1.56 (1.24–1.97) 1.39 (1.11–1.76) 1.19 (0.94–1.51) 1.00 0.0001
Model 2 1.25 (0.98–1.59) 1.26 (1.00–1.60) 1.09 (0.86–1.39) 1.00 0.007
Model 3 1.14 (0.88–1.47) 1.23 (0.96–1.37) 1.14 (0.88–1.47) 1.00 0.16
Fatal CHD
Rate/1,000 P-years 5.4 (102) 4.3 (82) 3.0 (59) 1.9 (39)
Model 1 1.91 (1.30–2.81) 1.70 (1.16–2.51) 1.32 (0.88–1.98) 1.00 0.0001
Model 2 1.48 (1.00–2.21) 1.50 (1.01–2.22) 1.15 (0.76–1.74) 1.00 0.002
Model 3 1.41 (0.92–2.16) 1.52 (1.00–2.32) 1.28 (0.82–1.98) 1.00 0.03
Nonfatal MI
Rate/1,000 P-years 6.5 (123) 5.6 (107) 4.9 (98) 4.2 (84)
Age-adjusted RR 1.39 (1.04–1.86) 1.25 (0.93–1.66) 1.14 (0.85–1.53) 1.00 0.04
Risk factor adjusted # 1.12 (0.82–1.51) 1.15 (0.86–1.53) 1.07 (0.79–1.44) 1.00 0.38
Case fatality (%) 49.1 41.1 36.7 28.7
Age-adjusted OR 1.40 (0.86–2.27) 1.40 (0.86–2.29) 1.19 (0.72–1.98) 1.00 P  0.03
 CRP  preexisting CHD 1.30 (0.80–2.14) 1.36 (0.83–2.22) 1.18 (0.71–1.96) 1.00 P  0.07
FEV1 (l)
1( 2.95) 2 (2.95–) 3 (3.41–) 4 (3.81–)
n 1,108 1,107 1,111 1,108
Major CHD
Rate/1,000 P-years 12.1 (228) 10.0 (190) 8.2 (161) 5.6 (115)
Model 1 1.66 (1.31–2.11) 1.44 (1.14–1.83) 1.32 (1.03–1.67) 1.00 0.0001
Model 2 1.28 (1.00–1.65) 1.18 (0.93–1.51) 1.17 (0.92–1.49) 1.00 0.002
Model 3 1.15 (0.88–1.50) 1.12 (0.87–1.43) 1.20 (0.93–1.55) 1.00 0.12
Fatal CHD
Rate/1,000 P-years 6.0 (112) 4.1 (78) 3.0 (59) 1.6 (33)
Model 1 2.41 (1.60–3.63) 1.80 (1.19–2.73) 1.57 (1.02–2.40) 1.00 0.0001
Model 2 1.81 (1.19–2.76) 1.46 (0.96–2.23) 1.37 (0.89–2.11) 1.00 0.0003
Model 3 1.63 (1.03–2.67) 1.46 (0.93–2.29) 1.42 (0.90–2.25) 1.00 0.01
Nonfatal MI
Rate/1,000 P-years 6.1 (116) 5.9 (112) 5.2 (102) 4.0 (82)
Age-adjusted RR 1.32 (0.97–1.79) 1.30 (0.97–1.73) 1.22 (0.91–1.63) 1.00 0.02
Risk factor adjusted # 1.02 (0.74–1.41) 1.04 (0.77–1.40) 1.09 (0.81–1.47) 1.00 0.35
Case fatality (%) 45.3 43.4 37.6 31.7
Age-adjusted OR 1.77 (1.06–2.95) 1.36 (0.81–2.27) 1.26 (0.74–2.13) 1.00 0.03
 CRP  preexisting CHD 1.65 (0.97–2.79) 1.31 (0.78–2.21) 1.22 (0.72–2.07) 1.00 0.06
Model 1, age adjusted; Model 2, Model 1  adjusted for BMI, smoking, physical activity, alcohol intake, social class, preexisting evidence of CHD (undiagnosed),
sBP, cholesterol, and HDL cholesterol; and Model 3, Model 2  CRP  IL-6. OR, odds ratio.
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to the association between reduced lung
function—in particular FVC—and type 2
diabetes, although the increased risk as-
sociated with low FEV1 compared with
high FEV1 remained signiﬁcant. Low
birth weight has been linked to both type
2 diabetes and adult lung function (24).
Thus, reduced lung function (FEV1) and
risk of type 2 diabetes may also be par-
tially determined by early growth.
Lung function and CHD
Although numerous studies have re-
ported an inverse relationship between
lung function (FEV1 or FVC) and risk of
CHD,theindependenceoftheassociation
has been inconsistent (1,2,22); few stud-
ies have differentiated between fatal and
nonfatal episodes. Our ﬁndings, based on
a larger number of events, conﬁrmed pre-
vious ﬁndings that reduced lung function
is associated more closely with increased
risk of fatal CHD than with nonfatal epi-
sodes (10) and predicts increased fatality
in the event of a cardiac event (10). The
associationwithfataleventswasindepen-
dent of cardiovascular risk factors and
was present in “never smokers.” In most
studies,fatalandnonfataleventsarecom-
bined due to perceptions concerning
common etiologies or limited power; this
may contribute to the inconsistent ﬁnd-
ings between studies. The reason for in-
creased incidence of fatal events with
poor lung function, in particular FEV1,
appears only partially explained by in-
ﬂammation (CRP, IL-6). The increased
riskoffatalCHDassociatedwithlowlung
function may potentially be due to ven-
triculardysrhythmiasorsilentMIs,which
are associated with poor lung function
and increased fatality (25), or due to the
increased risk of developing diabetes,
which also increases case fatality (25).
However, exclusion of the 85 men with
silent MIs on ECGs or incident diabetics
in the study and further adjustment for
arrthymias made little difference to the
ﬁndings.
Implications for diabetes and excess
risk of fatal CHD
The ﬁnding from this and other studies
suggest that reduced lung function not
only preceded the onset of diabetes but
alsocontinuedatanacceleratedpaceafter
the onset of diabetes (4). The increased
risk of fatal events and increased case fa-
tality associated with poor lung function
suggest that reduced lung function may
be another potential factor linking diabe-
testoincreasedriskofCHDandincreased
susceptibility to a fatal episode in the
event of a cardiac event (15,25). Specula-
tively, this association may reﬂect an im-
paired respiratory buffering capacity
needed in the context of a cardiac event to
cope with reduced cardiac output. Further
studiesarewarrantedtoseeifphysicaltrain-
ing might improve cardiorespiratory func-
tionintype2diabeticsandthusreducerisk
of fatal CHD.
Strengths and limitations
The strengths and limitations of the
present study require careful consider-
ation. The study is restricted to almost
exclusively white European men. How-
ever, the study population is socioeco-
nomically representative of middle-aged
men in the U.K. and follow-up rates are
exceptionally high. Ascertainment of
CHD death and MI is based on standard
methods. We were able to take into ac-
count evidence of CHD (diagnosed and
undiagnosed)withfactorsincludingECG
evidence of silent MIs and arrhythmias at
baseline and a wide range of cardiovascu-
lar risk factors. Despite adjusting risk es-
timates for several potential confounders
and mediators, we cannot rule out resid-
ual confounding. Although the associa-
tions persisted after adjustment for
established risk factors, it is possible that
this may be due to imprecision due to
adjustment for baseline levels only. The
current ﬁndings based on observational
epidemiological data cannot assess
causality.
CONCLUSIONS— In this study of
middle-aged men free of diagnosed CHD
strokeanddiabetes,restrictivepatternsof
lung function (reduced FVC and FEV1)
but not obstructive respiratory patterns
(reduced FEV1-to-FVC ratio) were in-
verselyassociatedwithincidenttype2di-
abetes and fatal CHD events independent
of established risk factors and metabolic
risk factors. The association between re-
duced lung function and fatal CHD and
type 2 diabetes in particular was to some
extent associated with inﬂammatory
pathways. Further studies are now
needed to extend such novel observa-
tions. The association between reduced
lung function and development of type 2
diabetes and fatal CHD events may pro-
vide another possible explanation for the
increased risk of fatal CHD in individuals
with type 2 diabetes.
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